Dr. Pusztai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 George St, New Haven
Suite 120
New Haven, CT 06520Fax+1 203-785-5792
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1992 - 1996
Semmelweis UniversityClass of 1986
Certifications & Licensure
CT State Medical License 2012 - 2025
TX State Medical License 1997 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2003
Clinical Trials
- Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Start of enrollment: 2001 Jan 01
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 51 citationsImmune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trialXiaotong Li, Sarah Warren, Vasiliki Pelekanou, Vikram B. Wali, Alessandra Cesano
Journal for Immunotherapy of Cancer. 2019-04-10 - 1059 citationsMeasurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyW. Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Mark Kuerer
Journal of Clinical Oncology. 2007-10-01 - 1627 citationsDevelopment and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingGarrett M. Frampton, Alex Fichtenholtz, Geoff Otto, Kai Wang, Sean R. Downing
Nature Biotechnology. 2013-11-01
Journal Articles
- Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women with ERBB2 (HER2)–Positive Breast CancerLajos Pusztai, MD, JAMA Network Open
- Association of T-cell Receptor Repertoire Use with Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTT...Lajos Pusztai, Jose Baselga, JAMA
Lectures
- Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Why Do We Care About Molecular Evolution in Breast Cancer?2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- 2013 Breast Cancer Symposium,American Society of Breast Surgeons, San Francisco, California - 9/7/2013
Press Mentions
Popular Weight Loss Drugs Now for Patients with Cancer?September 30th, 2024- Connecticut Magazine’s 2023 “Top Doctors” Issue Recognizes 82 Smilow Cancer Hospital and Yale Cancer Center PhysiciansMay 1st, 2023
- Discoveries & Impact (March 2023)March 16th, 2023
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
